AIMLogo.jpg
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
March 20, 2024 09:25 ET | AIM ImmunoTech Inc.
OCALA, Fla., March 20, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s...
logo 600X600.png
Feeding Tubes Market Size to Surpass Around US$ 9.69 Billion 2030, Recording a CAGR of 6.2% | Report by CoherentMI
March 20, 2024 06:21 ET | CMI
Burlingame, March 20, 2024 (GLOBE NEWSWIRE) -- CoherentMI published a report, titled, Feeding Tubes Market was valued at US$ 6.34 Billion in the year 2023 and is anticipated to reach US$ 9.69...
OBI Logo.jpg
OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform
March 18, 2024 05:00 ET | OBI Pharma Inc.
TAIPEI, Taiwan, March 18, 2024 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (TPEx: 4174) today announced preclinical data for OBI-992, a potential best-in-class anti-TROP2 Antibody-Drug Conjugate (ADC)....
OBI Logo.jpg
浩鼎将在 AACR 2024 年会   发表四篇论文
March 18, 2024 05:00 ET | OBI Pharma Inc.
台湾台北电, March 18, 2024 (GLOBE NEWSWIRE) -- 台湾浩鼎生技(4174)旗下自行开发的抗TROP2抗体药物复合体(ADC)OBI-992,临床前数据证明,它在多种动物实验模式均显示高效的抗 肿瘤活性、优异的药物动力学表现,和良好的安全性,具有发展为同类最佳抗TROP2 ADC的潜力。...
OBI Logo.jpg
浩鼎將在 AACR 2024 年會 發表四篇論文
March 18, 2024 05:00 ET | OBI Pharma Inc.
台灣台北電, March 18, 2024 (GLOBE NEWSWIRE) -- 台灣浩鼎生技(4174)旗下自行開發的抗TROP2抗體藥物複合體(ADC)OBI-992,臨床前數據證明,它在多種動物實驗模式均顯示高效的抗腫瘤活性、優異的藥物動力學表現,和良好的安全性,具有發展為同類最佳抗TROP2...
EH_finalists_031324v1_1080x1080_Finalists
CURE Media Group and Oncology Nursing News Announces the 2024 Extraordinary Healer® Award Finalists
March 15, 2024 12:00 ET | CURE Media Group
CRANBURY, N.J., March 15, 2024 (GLOBE NEWSWIRE) -- CURE® Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to more than 1 million patients,...
AIMLogo.jpg
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity
March 15, 2024 08:45 ET | AIM ImmunoTech Inc.
OCALA, Fla., March 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that it will present at the Virtual Investor Lunch Break: The AIM...
Immuneering-logo (1).png
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
March 14, 2024 07:00 ET | Immuneering Corporation
- IMM-1-104 has been well-tolerated, demonstrating the potential for a differentiated safety profile - - 100% suppression of acquired RAS alterations was observed in evaluable patients profiled for...
anocca.png
Anocca AB Licenses Gene Editing Technology from EmendoBio Inc.
March 14, 2024 02:00 ET | Anocca AB
NEW YORK and SÖDERTÄLJE, Sweden, March 14, 2024 (GLOBE NEWSWIRE) -- Anocca AB (Anocca), a leading T cell receptor-engineered T cell (TCR-T) cellular therapeutics company, and EmendoBio Inc....
PRECISION ONCOLOGY GLOBAL CLINICAL TRIAL LANDSCAPE (2024)
Novotech Publishes Precision Oncology Landscape Whitepaper Identifying Current Trends and Opportunities in Targeted Therapies
March 12, 2024 20:01 ET | Novotech
Novotech CRO has released an insightful whitepaper, Precision Oncology - Global Clinical Trial Landscape, providing the latest research insights for cancer